LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis
NCT ID: NCT00705900
Last Updated: 2008-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2007-01-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
LCD Solution: 2 applications / day
LCD
2 applications / day for 12 weeks
2
Calcipotriol cream: 2 applications / day
calcipotriol
2 applications / day for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LCD
2 applications / day for 12 weeks
calcipotriol
2 applications / day for 12 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able and willing to provide written informed consent
* diagnosed with chronic plaque psoriasis
* 3% to 15% body surface area involved
* in good general health
Exclusion Criteria
* renal or liver dysfunction
* pregnant or nursing
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NeoStrata Company, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Massachusettes General Hospital / Brigham Women's Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandra B Kimball, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusettes General Hospital / Brigham Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mass General Hospital: Clinical Unit for Research Trials in Skin
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Alora-Palli MB, Brouda I, Green B, Kimball AB. A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis. Arch Dermatol. 2010 Aug;146(8):919-22. doi: 10.1001/archdermatol.2010.167. No abstract available.
Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol. 2010;11(4):275-83. doi: 10.2165/11530380-000000000-00000.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-LCDPOP
Identifier Type: -
Identifier Source: org_study_id